Physician profile
Peter J Lloyd
NPI 1962717918
$4,043.58
in general payments reported to CMS, 2019-2025
39 companies · $668 in 2025
The $668 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $170 · 2022: $641 · 2023: $929 · 2024: $746 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.09 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $908.21 | 2019-2025 | |
| Amgen INC. | $603.59 | 2019-2025 | Enbrel, Otezla, Otezla |
| Lilly USA, LLC | $257.43 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $247.11 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $194.13 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.24 | 2023-2024 | Ofev, Spevigo |
| Pfizer INC. | $158.35 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $137.59 | 2019-2024 | |
| Janssen Biotech, INC. | $136.49 | 2023-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $99.30 | 2020-2023 | Acthar |
| Solta Medical, A Division of Bausch Health US, LLC | $94.45 | 2024-2025 | Clear+Brilliant |
| Actelion Pharmaceuticals US, INC. | $93.82 | 2023 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $93.14 | 2019-2024 | Benlysta |
| Ucb, INC. | $92.15 | 2023-2025 | Bimzelx, Cimzia |
| Fresenius Kabi USA, LLC | $89.00 | 2023-2025 | Idacio |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $68.46 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $48.60 | 2019-2025 | Libtayo |
| Genzyme Corporation | $43.45 | 2019-2023 | |
| Organogenesis INC. | $42.34 | 2024-2025 | Novachor |
| Radius Health, INC. | $41.60 | 2019-2025 | |
| Tersera Therapeutics LLC | $39.51 | 2025 | Quzyttir |
| Mallinckrodt Enterprises LLC | $30.76 | 2019 | |
| Almatica Pharma LLC | $29.38 | 2024 | Teriparatide |
| Pacira Therapeutics, INC. | $27.90 | 2019 | |
| Biocon Biologics INC | $23.15 | 2023 | Hulio |
| Sanofi-Aventis U.S. LLC | $22.20 | 2019 | |
| Kyowa Kirin, INC. | $21.97 | 2024 | |
| Angiodynamics, INC. | $20.68 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $20.57 | 2022 | |
| Celgene Corporation | $19.58 | 2019 | |
| Merz North America, INC. | $19.44 | 2019 | |
| Incyte Corporation | $18.91 | 2023 | Opzelura |
| Mission Pharmacal Company | $18.05 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.00 | 2024 | Arcalyst |
| Boston Scientific Corporation | $17.94 | 2020 | |
| Bsn Medical INC | $17.37 | 2020 | |
| Allergan, INC. | $16.40 | 2019 | |
| Horizon Therapeutics Plc | $14.06 | 2023 | Krystexxa |
| Biofrontera INC. | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.